Effect of CYP 3A perpetrators on ibrutinib exposure in healthy participants-Reference-Cited by-同舟云学术

Effect of CYP 3A perpetrators on ibrutinib exposure in healthy participants

Published:2015-06-24 Issue:4 Volume:3 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Jong Jan¹,Skee Donna²,Murphy Joe²,Sukbuntherng Juthamas³,Hellemans Peter⁴,Smit Johan⁴,Vries Ronald⁴,Jiao Juhui James²,Snoeys Jan⁴,Mannaert Erik⁴

Affiliation:

1. Janssen Research & Development San Diego California

2. Janssen Research & Development Raritan New Jersey

3. Pharmacyclics Inc. Sunnyvale California

4. Janssen Research & Development Beerse Belgium

Funder

Janssen Research & Development, LLC

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.156

Reference25 articles.

1. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

2. Grapefruit juice‐felodipine interaction: reproducibility and characterization with the extended release drug formulation;Bailey DG;Br J Clin Pharmacol,1995

3. Comparison of Endogenous 4β-Hydroxycholesterol with Midazolam as Markers for CYP3A4 Induction by Rifampicin

4. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

5. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice*

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08

2. Clinical Trial Data-Driven Risk Assessment of Drug–Drug Interactions: A Rapid and Accurate Decision-Making Tool;Clinical Pharmacokinetics;2024-08

3. Evaluation and Optimization of a Microcavity Plate–Based Human Hepatocyte Spheroid Model for Predicting Clearance of Slowly Metabolized Drug Candidates;Drug Metabolism and Disposition;2024-05-22

4. Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment;British Journal of Clinical Pharmacology;2023-11-13

5. Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma;The European Research Journal;2023-11-04